Table of contents
July 2008 Volume 5 No 7
Editorial
Lost in translation—prognostic signatures for breast cancer
363doi:10.1038/ncponc1177 | Full Text | PDF (100K)
Research Highlights
SATB1 expression generates gene-expression profiles that promote breast tumor metastasis
364IMP3 expression determines aggressive superficial urothelial carcinoma
364Pfetin predicts outcome for patients with gastrointestinal stromal tumors
364KRAS wild-type status predicts response to cetuximab in metastatic colorectal cancer
365Young patients with multiple myeloma: favorable prognostic factors and better survival
365No survival benefit in follicular lymphoma with first-line intensive chemoimmunotherapy
366High lymph-node yield improves the prognostic value of esophageal cancer staging
366Imiquimod 5% cream treats vulvar intraepithelial neoplasia effectively
367Practice Points
Prognosis and outcomes of lymphocyte-predominant Hodgkin's lymphoma
368doi:10.1038/ncponc1153 | Full Text | PDF (128K)
S-1 adjuvant chemotherapy for advanced gastric cancer
370doi:10.1038/ncponc1152 | Full Text | PDF (126K)
Does lenalidomide plus dexamethasone improve outcome in patients with relapsed multiple myeloma?
372doi:10.1038/ncponc1138 | Full Text | PDF (125K)
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
374doi:10.1038/ncponc1151 | Full Text | PDF (127K)
Viewpoint
Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer
376Estrogen-receptor expression is a useful predictive marker of response to endocrine therapy in patients with breast cancer. The authors of this Viewpoint discuss the use of gene-expression profiles and predictive markers for determining the optimum treatment strategy for women with breast cancer.
doi:10.1038/ncponc1139 | Full Text | PDF (123K)
Reviews
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
378Bevacizumab, sorafenib, sunitinib and temsirolimus have been approved for use in patients with advanced solid cancers. Many other drugs with activity in preclinical models, however, have failed to show efficacy in clinical trials. The authors of this Review describe the studies that led to the approval of these antiangiogenic agents, discuss the potential value of biomarkers of angiogenesis, and provide rationale for future developments.
doi:10.1038/ncponc1150 | Full Text | PDF (581K)
Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas
393Brain tumors may harbor small subpopulations of cells that share characteristics of neural stem cells. The use of neural stem cells and progenitor cells as delivery vehicles of molecules toxic to tumors offers a promising experimental treatment strategy. This Review summarizes recent advances in the basic understanding of neural stem cell and cancer-stem-cell biology and the progress towards translating these novel concepts into the clinic.
doi:10.1038/ncponc1132 | Full Text | PDF (630K)
Technology Insight: image-guided robotic radiosurgery—a new approach for noninvasive ablation of spinal lesions
405Spinal radiosurgery was developed to overcome the limitations associated with invasive surgery and traditional radiotherapetuic approaches for the treatment of these lesions. The authors of this Review discuss the benefits of this new therapeutic technique, such as low rate of complications, durable pain relief and local tumor control while maintaining physical and mental quality of life.
doi:10.1038/ncponc1131 | Full Text | PDF (555K)
Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer
415More-effective systemic therapies are needed for colorectal cancer, and particularly for metastatic disease, for which median survival rates remain below 2 years. The addition of panitumumab to best supportive care has improved efficacy in patients with chemotherapy-refractory metastatic disease, and is associated with a favorable safety profile. The authors discuss the available data and ongoing investigations of this agent in the first-line and second-line settings.
doi:10.1038/ncponc1136 | Full Text | PDF (242K)
Case Study
Lumpectomy and partial breast irradiation for early-stage breast cancer following mantle irradiation for Hodgkin's lymphoma
426Patients treated with irradiation for Hodgkin's lymphoma are at increased risk of breast cancer. Alm El-Din et al. report the case of a 57-year-old woman who was diagnosed with breast cancer 15 years after receiving mantle irradiation for Hodgkin's lymphoma and was managed with lumpectomy and partial breast irradiation. The authors suggest partial breast irradiation as a feasible approach for women who develop breast cancer after Hodgkin's lymphoma and decline mastectomy.
doi:10.1038/ncponc1135 | Full Text | PDF (202K)
